Showing results (41-50 of 57) with videos related to
Sort By:
Pageof 6
Hepatology Communications|December 6, 2023
FAT4 loss initiates hepatocarcinogenesis through the switching of canonical to noncanonical WNT signaling pathwaysFung-Yu Huang, Danny Ka-Ho Wong, Lung-Yi Mak, et al.Journal of Hepatology|March 25, 2024
ALT to qHBsAg ratio predicts long-term HBsAg seroclearance after entecavir cessation in Chinese patients with chronic hepatitis BRyan Hin-Man Leung, Rex Wan-Hin Hui, Lung-Yi Mak, et al.Journal of Viral Hepatitis|September 9, 2024
Cigarette Smoking Is Associated With Lower Chance of Hepatitis B Surface Antigen Seroclearance and Altered Host ImmunityTsz-Yan Kwok, Rex Wan-Hin Hui, XianHua Mao, et al.Hepatology (Baltimore, Md.)|September 21, 2022
Glycemic burden and the risk of adverse hepatic outcomes in patients with chronic hepatitis B with type 2 diabetesLung-Yi Mak, Rex Wan-Hin Hui, Chi-Ho Lee, et al.Alimentary Pharmacology & Therapeutics|September 10, 2024
Glycaemic control is a modifiable risk factor for hepatocellular carcinoma and liver-related mortality in patients with diabetesXianhua Mao, Ka-Shing Cheung, Jing-Tong Tan, et al.Gut|April 3, 2024
Optimal glycaemic control and the reduced risk of colorectal adenoma and cancer in patients with diabetes: a population-based cohort studyXianhua Mao, Ka Shing Cheung, Jing-Tong Tan, et al.Liver International : Official Journal of the International Association for the Study of the Liver|March 27, 2019
Association of adipokines with hepatic steatosis and fibrosis in chronic hepatitis B patients on long-term nucleoside analogueLung-Yi Mak, Chi-Ho Lee, Ka-Shing Cheung, et al.Hepatology (Baltimore, Md.)|March 27, 2024
Effects of empagliflozin on liver fat in patients with metabolic dysfunction-associated steatotic liver disease without diabetes mellitus: A randomized, double-blind, placebo-controlled trialKa Shing Cheung, Ho Yu Ng, Rex Wan Hin Hui, et al.Gut|August 5, 2025
Large-scale profile study on hepatitis B surface antigen levels in chronic hepatitis B: implications for drug development targeting functional cureRex Wan-Hin Hui, Trevor Kwan-Hung Wu, Karen Cheuk-Ying Ho, et al.JHEP Reports : Innovation in Hepatology|October 16, 2025
Disparate patterns of disease time burden in patients with HCC on immunotherapy or tyrosine kinase inhibitorsRex Wan-Hin Hui, Matthew Shing-Hin Chung, Lu Li, et al.Pageof 6